HedgePath Pharmaceuticals, Inc. (HPPI) is a publicly traded company in the Unknown sector. Across all available filings, 11 corporate insiders have executed 48 transactions totaling $28.3K, demonstrating a bearish sentiment with -$25.7K in net insider flow. The most recent transaction on Jan 15, 2019 involved a transaction of 362,121 shares valued at $0.
No significant insider buying has been recorded for HPPI in the recent period.
No significant insider selling has been recorded for HPPI in the recent period.
Based on recent SEC filings, insider sentiment for HPPI is bearish with an Insider Alignment Score of 5/100 and a net flow of -$25.7K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at HedgePath Pharmaceuticals, Inc. (HPPI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 11 insiders are actively trading HPPI stock, having executed 48 transactions in the past 90 days. The most active insider is Nicholas J. Virca (Executive), who has made 2 transactions totaling $2.1M.
Get notified when executives and directors at HPPI file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 15, 2019 | International Pty Ltd Mayne Pharma | Executive | Other | 362,121 | $N/A | $0 | |
| Dec 20, 2018 | Brendan Magrab E. | Executive | Award | 65,000 | $0.08 | $5.2K | |
| Dec 20, 2018 | Daniel Martin Robert | Executive | Award | 60,000 | $0.08 | $4.8K | |
| Aug 30, 2018 | J. Hasara Garrison | Executive | Sale | 100,000 | $0.27 | $27.0K | |
| Jul 15, 2018 | Ventures Pty Ltd Mayne Pharma | Executive | Other | 184,798 | $N/A | $0 | |
| Dec 19, 2017 | International Pty Ltd Mayne Pharma | Executive | Purchase | 600,000 | $N/A | $0 | |
| Dec 19, 2017 | Cross Stefan | Executive | Purchase | 600,000 | $N/A | $0 | |
| Jun 30, 2017 | Hedgepath, Llc | Executive | Sale | 2,500,000 | $N/A | $0 | |
| Mar 8, 2017 | Dana Ono Richard | Executive | Option Exercise | 300,000 | $N/A | $0 | |
| Mar 8, 2017 | Dana Ono Richard | Executive | Payment | 118,800 | $0.34 | $40.4K | |
| Mar 8, 2017 | Dana Ono Richard | Executive | Payment | 118,800 | $0.34 | $40.4K | |
| Mar 8, 2017 | Dana Ono Richard | Executive | Option Exercise | 300,000 | $N/A | $0 | |
| Mar 8, 2017 | Dana Ono Richard | Executive | Option Exercise | 150,000 | $N/A | $0 | |
| Mar 8, 2017 | Dana Ono Richard | Executive | Payment | 59,400 | $0.34 | $20.2K | |
| Mar 8, 2017 | Cross Stefan | Executive | Option Exercise | 300,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Payment(F) | 9 | $3.4M | 61.0% |
Award(A) | 5 | $1.6M | 29.2% |
Other(J) | 7 | $513.6K | 9.3% |
Sale(S) | 5 | $27.0K | 0.5% |
Purchase(P) | 5 | $1.3K | 0.0% |
Exercise(M) | 11 | $0 | 0.0% |
Exercise (Options)(X) | 5 | $0 | 0.0% |
Conversion(C) | 1 | $0 | 0.0% |
Insider selling pressure at HedgePath Pharmaceuticals, Inc. has increased, with 11 insiders executing 48 transactions across all time. Total sales of $27.0K significantly outpace purchases of $1.3K, resulting in a net outflow of $25.7K. This selling activity appears largely discretionary, which may warrant closer attention from investors.